News

POTOMAC, MARYLAND – December 09, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for

New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma’s Leadership in Alzheimer’s Innovation

POTOMAC, MARYLAND – November 25, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for

POTOMAC, MARYLAND / November 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease,

POTOMAC, MARYLAND – November 13, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence (“AI”) to develop innovative

POTOMAC, MARYLAND November 10, 2025 / IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced

POTOMAC, MARYLAND – November 03, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for

POTOMAC, MARYLAND – October 22, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today

POTOMAC, MARYLAND – October 14, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for

POTOMAC, MARYLAND October 10, 2025 / IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced